Program
Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
Thursday, January 7
Friday, january 8
- Plenary Session 1: Reframing the Tumor Microenvironment in Radiotheranostics
- Plenary Session 2: New Frontiers in Radiotheranostic Development
- Plenary Session 3: From Discovery to Patient Care: Clinical Translation in Radioligand Therapy
- Panel Discussion: Forging Academic, Industry, and Government Partnerships
Saturday, January 9
- Plenary Session 4: Radiotheranostics at the Interface of Cancer and Immunity
- Plenary Session 5: Systems-Level Insights into Response and Resistance
- Plenary Session 6: Molecular Imaging as a Window into Treatment Response
- Panel Discussion: Who Owns Radioligand Therapy? Rethinking Training and Clinical Identity
sunday, january 10
- Plenary Session 7: Preparing the Next Generation of Radiotheranostics Leaders
- Closing Keynote Lecture
REGISTRATION
3-9 p.m.
WELCOME AND OPENING Keynote
- 5 p.m. | Welcome and Conference Introduction
David R. Piwnica-Worms, The University of Texas MD Anderson Cancer Center, Houston, Texas - 5:30 p.m. | Opening Keynote Lecture
Theranostics revolution: Seeing, targeting, treating
Jason S. Lewis, Memorial Sloan Kettering Cancer Center, New York City, New York
Opening Reception
6:15-7:15 p.m.
continental breakfast
7-8:30 a.m.
Roundtables Networking Session
7:15-8:15 a.m.
Plenary Session 1: Reframing the Tumor Microenvironment in Radiotheranostics
8:30-10:15 a.m.
Session Chair: David R. Piwnica-Worms, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 8:35 a.m. | David R. Piwnica-Worms
- 8:55 a.m. | Immuno-radiobiological effects of radiopharmaceutical therapies in the tumor microenvironment
Zachary Morris, University of Wisconsin-Madison School of Medicine & Public Health, Madison, Wisconsin - 9:15 a.m. | Targeting stroma to overcome therapeutic resistance in solid tumors
Ellen Puree University of Pennsylvania, Philadelphia, Pennsylvania - 9:35 a.m. | Short talk selected from proffered abstract
- 9:45 a.m. | Short talk selected from proffered abstract
- 9:55 a.m. | Panel Discussion/Q&A
Break
10:30-10:45 a.m.
Plenary Session 2: New Frontiers in Radiotheranostic Development
10:45 a.m.-12:30 p.m.
Session Chair: Julie L. Sutcliffe, University of California, Davis, California
- 10:50 a.m. | Julie L. Sutcliffe
- 11:10 a.m. | Novel theranostic radionuclides and potential use
Cathy Cutler, Brookhaven National Laboratory, Rochester, New York - 11:30 a.m. | Speaker to be announced
- 11:50 a.m. | Short talk selected from proffered abstract
- 12 p.m. | Short talk selected from proffered abstract
- 12: 10 p.m. | Panel Discussion/Q&A
Lunch on own
12:45-2:30 p.m.
Plenary Session 3: From Discovery to Patient Care: Clinical Translation in Radioligand Therapy
2:30-4:30 p.m.
Session Chair: To be announced
- 2:35 p.m. | Translation of novel radioligand therapy into the clinic
Andrew Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia - 2:55 p.m. | Speaker to be announced
- 3:15 p.m. | Learning from Imaging Protein-Based Agents in Patients to Guide Precision Oncology
Elisabeth de Vries, University Medical Center Groningen, Groningen, Netherlands - 3:35 p.m.| Short talk selected from proffered abstract
- 3:45 p.m. | Short talk selected from proffered abstract
- 3:55 p.m. | Panel Discussion/Q&A
Break
4:30-4:45 p.m.
Panel Discussion: Forging Academic, Industry, and Government Partnerships
4:45-5:45 p.m.
Moderator: To be announced
- Panelists
Jeevan Virk, Sego Therapeutics, Salt Lake City, Utah
Pushpa Tandon, NCI, Rockville, Maryland
Freddy E. Escorcia, RayzeBio, San Diego, California
Additional panelists to be announced
Poster Session A/Reception
5:45-6:45 p.m.
continental breakfast
7-8:30 a.m.
Roundtables Networking Session
7:15-8:15 a.m.
Plenary Session 4: Radiotheranostics at the Interface of Cancer and Immunity
8:30 -10:30 a.m.
Session Chair: To be announced
- 8:35 a.m. | Speaker to be announced
- 8:55 a.m. | Barriers to radiation immunogenicity
Silvia Formenti, Weill Cornell University, New York City, New York - 9:15 a.m. | Speaker to be announced
- 9:35 a.m. | Short talk selected from proffered abstract
- 9:45 a.m. | Short talk selected from proffered abstract
- 9:55 a.m. | Panel Discussion/Q&A
Break
10:35-10:45 a.m.
Plenary Session 5: Systems-Level Insights into Response and Resistance
10:45 a.m.-12:45 p.m.
Session Chair: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
- 10:50 a.m. | Speaker to be announced
- 11:10 a.m. | Speaker to be announced
- 11:30 a.m. | Margie Sutton, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 11:50 a.m. | Short talk selected from proffered abstract
- 12 p.m. | Short talk selected from proffered abstract
- 12:10 p.m. | Panel Discussion/Q&A
Lunch on own
12:45-2:30 p.m.
Plenary Session 6: Molecular Imaging as a Window into Treatment Response
2:30-4:30 p.m.
Session Chair: Kayvan R. Keshari, Memorial Sloan Kettering Cancer Center, New York City, New York
- 2:35 p.m. | Kayvan R. Keshari
- 2:55 p.m. | Combination strategies for dual tumor and stoma theranostics
Edwinn C. Pratt, Stony Brook University, Renaissance School of Medicine, New York City, New York - 3:15 p.m. | Molecular imaging of therapy response by PET
Eric Aboagye, Imperial College London, London, United Kingdom - 3:35 p.m.| Short talk selected from proffered abstract
- 3:45 p.m. | Short talk selected from proffered abstract
- 3:55 p.m. | Panel Discussion/Q&A
Break
4:30-4:45 p.m.
Panel Discussion: Who Owns Radioligand Therapy? Rethinking Training and Clinical Identity
4:45-5:45 p.m.
Moderator: David Mankoff, University of Pennsylvania, Philadelphia, Pennsylvania
- Panelists
Julian Adams, Stand Up To Cancer (SU2C), Los Angeles, California
Douglas R. Spitz, University of Iowa, Iowa City, Iowa
Freddy E. Escorcia, RayzeBio, San Diego, California
Jason Lewis, Memorial Sloan Kettering Cancer Center, New York City, New York
Additional panelists to be announced
Poster Session A/Reception
5:45-7:45 p.m.
continental breakfast
7-8 a.m.
Plenary Session 7: Preparing the Next Generation of Radiotheranostics Leaders
8-10 a.m.
Session Chair: To be announced
- 8:05 a.m. | Training theranostics specialists: Clinicians and clinician-scientists
David Mankoff, University of Pennsylvania, Philadelphia, Pennsylvania - 8:25 a.m. | Speaker to be announced
- 8:45 a.m. | Panel Discussion/Q&A
Break
10-10:15 a.m.
Closing Keynote Lecture
10-11 a.m.
Closing Remarks
11:00-11:15 a.m.
- Kayvan R. Keshari, Memorial Sloan Kettering Cancer Center, New York City, New York